Avapritinib
Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines CorporationSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Relapsed or Refractory Myeloid Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mitoxantrone First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cladribine University of Washington | Phase 2 | BBB |
Cyclophosphamide Prelude Therapeutics | Phase 3 | BB |
Venetoclax First Affiliated Hospital of Zhejiang University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →